FDA Clears AI-Powered Prostate Volume Measurement for Handheld Ultrasound
Offering expedited calculation of prostate volume, Clarius Prostate AI is reportedly the first AI-enabled prostate measurement tool to garner FDA clearance for use with handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius Prostate AI, an artificial intelligence (AI) application for handheld ultrasound that enables rapid calculation of prostate volume.
In contrast to manual processes with traditional ultrasound, clinicians can utilize the Clarius app to access Clarius Prostate AI, which highlights the prostate gland and facilitates caliper placement to measure prostate volume, according to Clarius, the developer of Clarius Prostate AI.
The newly FDA-cleared Clarius Prostate AI, which enables rapid calculation of prostate volume with handheld ultrasound, is currently available with Clarius handheld ultrasound scanners that allow customization for urology exams. (Image courtesy of Clarius Mobile Health.)
The company said Clarius Prostate AI, which is being showcased at the American Urological Association (AUA) conference April 26-29, also calculates prostate-specific antigen (PSA) density by combining the prostate volume measurement with the inputted patient’s PSA level.
"95% of clinicians we recently surveyed believe AI-powered measurements would save them time and allow them to see more patients. Manual ultrasound prostate volume measurements are repetitive and time-consuming, regardless of experience. With Clarius Prostate AI, what used to take several minutes now takes seconds, no matter your experience level,” noted Sarah Leverett, the vice president of marketing at Clarius Mobile Health.
Clarius noted that Clarius Prostate AI is currently available with Clarius handheld ultrasound scanners, including the C3 HD3 for transabdominal ultrasound and the EC7 HD3 for transrectal imaging, that offer customization for urology exams.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
